Abstract:The human β1‐adrenergic receptor (β1AR) carries common (S49G) and rare (R31Q, A29T) single‐nucleotide polymorphisms (SNPs) in its extracellular N‐terminal domain. These were found to alter receptor O‐glycosylation and/or proteolytic cleavage, resulting in SNP‐dependent differences in β1AR cell surface expression and function that also involved the common C‐terminal R389G polymorphism. Thus, GPCR SNPs can modify receptor processing and function even when located outside well‐known domains that govern ligand binding and activation. N‐terminal nonsynonymous single‐nucleotide polymorphisms (SNPs) of G protein‐coupled receptors (GPCRs) are common and often affect receptor post‐translational modifications. Their functional implications are, however, largely unknown. We have previously shown that the human β1‐adrenergic receptor (β1AR) is O‐glycosylated in the N‐terminal extracellular domain by polypeptide GalNAc transferase‐2 that co‐regulates receptor proteolytic cleavage. Here, we demonstrate that the common S49G and the rare A29T and R31Q SNPs alter these modifications, leading to distinct effects on receptor processing. This was achieved by in vitro O‐glycosylation assays, analysis of native receptor N‐terminal O‐glycopeptides, and expression of receptor variants in cell lines and neonatal rat ventricular cardiomyocytes deficient in O‐glycosylation. The SNPs eliminated (S49G) or introduced (A29T) regulatory O‐glycosites that enhanced or inhibited cleavage at the adjacent sites (P52↓L53 and R31↓L32), respectively, or abolished the major site at R31↓L32 (R31Q). The inhibition of proteolysis of the T29 and Q31 variants correlated with increased full‐length receptor levels at the cell surface. Furthermore, the S49 variant showed increased isoproterenol‐mediated signaling in an enhanced bystander bioluminescence energy transfer β‐arrestin2 recruitment assay in a coordinated manner with the common C‐terminal R389G polymorphism. As Gly at position 49 is ancestral in placental mammals, the results suggest that its exchange to Ser has created a β1AR gain‐of‐function phenotype in humans. This study provides evidence for regulatory mechanisms by which GPCR SNPs outside canonical domains that govern ligand binding and activation can alter receptor processing and function. Further studies on other GPCR SNPs with clinical importance as drug targets are thus warranted.

N-glycosylation of α1D-adrenergic receptor N-terminal domain is required for correct trafficking, function, and biogenesis

N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation

N-glycosylation of the β2 adrenergic receptor regulates receptor function by modulating dimerization

The Role of N‐glycosylation in the Stability, Trafficking and GABA‐uptake of GABA‐transporter 1

The role of N-glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal N-glycans facilitate efficient GABA-uptake activity of the GABA transporter.

N-Glycosylation Regulates the Trafficking and Surface Mobility of GluN3A-Containing NMDA Receptors

Role Ofn-Linked Glycosylation in Biosynthesis, Trafficking, and Function of the Human Glucagon-Like Peptide 1 Receptor

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor

Altered O‐glycosylation of β1‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity

Importance of N-linked Glycosylation in the Functional Expression of Murine CD1d1.

A mutation in the hamster alpha(1B)-adrenergic receptor that differentiates two steps in the pathway of receptor internalization

N-linked glycosylation of the mGlu7 receptor regulates the forward trafficking and transsynaptic interaction with Elfn1

Regulated N-glycosylation controls chaperone function and receptor trafficking

Monitoring the glycosylation of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionate‐type glutamate receptors using specific antibodies reveals a novel regulatory mechanism of N‐glycosylation occupancy by molecular chaperones in mice

Deciphering the role of glycosaminoglycans in GPCR signaling

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

Substrate-directed control of N-glycosylation in the endoplasmic reticulum calibrates signal reception at the cell-surface

Big1, A Brefeldin A-Inhibited Guanine Nucleotide-Exchanae Protein, Is Required For Correct Glycosylation And Function Of Integrin Beta 1

Multiple N-glycans Cooperate in Balancing Misfolded BRI1 Secretion and ER Retention

N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains

Control of cell surface expression of GABAA receptors by a conserved region at the end of the N-terminal extracellular domain of receptor subunits